THE NOVEL BISPECIFIC CD47-CD19 ANTIBODY TG-1801 POTENTIATES THE ACTIVITY OF UBLITUXIMAB-UMBRALISIB (U2) DRUG COMBINATION IN PRECLINICAL MODELS OF B-NHL
THE NOVEL BISPECIFIC CD47-CD19 ANTIBODY TG-1801 POTENTIATES THE ACTIVITY OF UBLITUXIMAB-UMBRALISIB (U2) DRUG COMBINATION IN PRECLINICAL MODELS OF B-NHL
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now